Royce & Associates LP raised its holdings in SiBone (NASDAQ:SIBN – Free Report) by 15.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 457,088 shares of the company’s stock after acquiring an additional 62,000 shares during the quarter. Royce & Associates LP’s holdings in SiBone were worth $8,593,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Versant Capital Management Inc grew its holdings in shares of SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after purchasing an additional 887 shares in the last quarter. D.A. Davidson & CO. increased its position in shares of SiBone by 2.8% in the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock worth $711,000 after purchasing an additional 1,038 shares during the last quarter. State of Wyoming raised its stake in SiBone by 70.8% in the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after purchasing an additional 4,490 shares in the last quarter. Diversified Trust Co raised its position in shares of SiBone by 26.0% during the 3rd quarter. Diversified Trust Co now owns 34,775 shares of the company’s stock valued at $654,000 after buying an additional 7,165 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in shares of SiBone by 58.2% during the 1st quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock worth $372,000 after acquiring an additional 10,848 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the stock. Needham & Company LLC cut their target price on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. TD Cowen increased their target price on SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday, November 3rd. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, Truist Financial upped their price objective on SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.00.
Read Our Latest Research Report on SiBone
Insiders Place Their Bets
In other news, CEO Laura Francis sold 75,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $25.30, for a total transaction of $1,897,500.00. Following the transaction, the chief executive officer directly owned 304,256 shares of the company’s stock, valued at approximately $7,697,676.80. The trade was a 19.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Dunn sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $20.89, for a total value of $417,800.00. Following the transaction, the director owned 16,057 shares of the company’s stock, valued at approximately $335,430.73. This represents a 55.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 358,722 shares of company stock valued at $7,765,415 in the last 90 days. 4.00% of the stock is owned by corporate insiders.
SiBone Stock Performance
Shares of SIBN stock opened at $23.16 on Wednesday. The stock has a 50 day moving average price of $20.56 and a two-hundred day moving average price of $16.85. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $25.92. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.15 and a current ratio of 7.58. The company has a market capitalization of $1.04 billion, a P/E ratio of -74.71 and a beta of 0.64.
SiBone (NASDAQ:SIBN – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. The business had revenue of $55.70 million during the quarter, compared to analysts’ expectations of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. Analysts expect that SiBone will post -0.34 earnings per share for the current year.
About SiBone
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
Read More
- Five stocks we like better than SiBone
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SiBone (NASDAQ:SIBN – Free Report).
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
